{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:06:55Z","timestamp":1792796815711,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2001,10]]},"DOI":"10.1136\/ard.60.10.913","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:37:40Z","timestamp":1027766260000},"page":"913-923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":127,"title":["Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine"],"prefix":"10.1016","volume":"60","author":[{"given":"D L","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J R","family":"Kalden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L B A","family":"van de Putte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T K","family":"Kvien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Schattenkirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Oed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Loew-Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.60.10.913_bib1","first-page":"1","article-title":"The bone and joint decade 2000\u20132010 [editorial].","volume":"27","author":"Hazes","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.60.10.913_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis.","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.10.913_bib3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.1780351003","article-title":"Use of short-term efficacy\/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a meta-analysis of published clinical trials.","volume":"35","author":"Felson","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.10.913_bib4","first-page":"S71","article-title":"Currently used second-line agents: do they control the disease course?","volume":"15(suppl 17)","author":"van de Putte","year":"1997","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.60.10.913_bib5","first-page":"S75","article-title":"Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis.","volume":"15(suppl 17)","author":"Wolfe","year":"1997","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.60.10.913_bib6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF00192310","article-title":"Effects of leflunomide on immune responses and models of inflammation.","volume":"14","author":"Bartlett","year":"1993","journal-title":"Springer Semin Immunopathol"},{"key":"10.1136\/ard.60.10.913_bib7","doi-asserted-by":"crossref","first-page":"21682","DOI":"10.1074\/jbc.273.34.21682","article-title":"Leflunomide inhibits pyrimidine de novo sythesis in mitogen-stimulated T-lymphocytes from healthy humans.","volume":"273","author":"R\u00fcckemann","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.60.10.913_bib8","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.1780381111","article-title":"Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study.","volume":"38","author":"Mladenovic","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.10.913_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","article-title":"Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial.","volume":"353","author":"Smolen","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.60.10.913_bib10","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate.","volume":"159","author":"Strand","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1136\/ard.60.10.913_bib11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","article-title":"A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.","volume":"39","author":"Emery","year":"2000","journal-title":"Rheumatology (Oxford)."},{"key":"10.1136\/ard.60.10.913_bib12","first-page":"20","article-title":"Mechanism of action of leflunomide in rheumatoid arthritis.","volume":"25(suppl 53)","author":"Fox","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.60.10.913_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0049-0172(99)80034-1","article-title":"Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis.","volume":"29","author":"Kremer","year":"1999","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.60.10.913_bib14","doi-asserted-by":"crossref","first-page":"29682","DOI":"10.1074\/jbc.270.50.29682","article-title":"Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans.","volume":"270","author":"Fairbanks","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.60.10.913_bib15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.59.11.841","article-title":"Leflunomide: mode of action in the treatment of rheumatoid arthritis.","volume":"59","author":"Breedveldt","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.60.10.913_bib16","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.4049\/jimmunol.162.4.2095","article-title":"Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-\u03baB activation and gene expression.","volume":"162","author":"Manna","year":"1999","journal-title":"J Immunol"},{"key":"10.1136\/ard.60.10.913_bib17","first-page":"213","article-title":"Leflunomide's active metabolite A77\u20131726 and its derivatives, the malononitrilamides, inhibit the generation of oxygen radicals in mononuclear phagocytes.","volume":"14","author":"Schorlemmer","year":"1998","journal-title":"International Journal of Immunotherapy"},{"key":"10.1136\/ard.60.10.913_bib18","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/1529-0131(200007)43:7<1488::AID-ANR11>3.0.CO;2-G","article-title":"Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients.","volume":"43","author":"Kraan","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.10.913_bib19","first-page":"663","article-title":"Exposure of T lymphocytes to leflumonide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1\u03b2 and metalloproteinases.","volume":"9","author":"Deage","year":"1998","journal-title":"Eur Cytokine Netw"},{"key":"10.1136\/ard.60.10.913_bib20","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/1529-0131(200008)43:8<1820::AID-ANR18>3.0.CO;2-D","volume":"43","author":"Kraan","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.10.913_bib21","first-page":"1747","article-title":"Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind, placebo controlled study.","volume":"15","author":"Borg","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.60.10.913_bib22","first-page":"1524","article-title":"Comparison of standard and alternative health assessment questionnaire scoring procedures for documenting functional outcomes in patients with rheumatoid arthritis.","volume":"23","author":"Tomlin","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.60.10.913_bib23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/028418517701800415","article-title":"Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films.","volume":"18","author":"Larsen","year":"1977","journal-title":"Acta Radiol Diagn"},{"key":"10.1136\/ard.60.10.913_bib24","series-title":"Controversies in the clinical evaluation of analgesic - anti-inflammatory - antirheumatic drugs.","first-page":"323","article-title":"Radiographic evaluation of rheumatoid arthritis in therapeutic trials.","author":"Larsen","year":"1980"},{"key":"10.1136\/ard.60.10.913_bib25","first-page":"561","article-title":"Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles.","volume":"20","author":"Goldsmith","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.60.10.913_bib26","first-page":"557","article-title":"Minimum important difference between patients with rheumatoid arthritis: the patient's perspective.","volume":"20","author":"Wells","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.60.10.913_bib27","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/1529-0131(200003)43:3<506::AID-ANR5>3.0.CO;2-U","volume":"43","author":"Tugwell","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.10.913_bib28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U","article-title":"Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis.","volume":"43","author":"Sharp","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.10.913_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.52.6.423","article-title":"Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient?","volume":"52","author":"Capell","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.60.10.913_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/rheumatology\/29.3.201","article-title":"Tolerability of enteric-coated sulphasalazine in rheumatoid arthritis: results of a co-operating clinics study.","volume":"29","author":"Donovan","year":"1990","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.60.10.913_bib31","first-page":"1880","article-title":"Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine.","volume":"25","author":"Capell","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.60.10.913_bib32","first-page":"2123","article-title":"Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials.","volume":"26","author":"Weinblatt","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.60.10.913_bib33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/ard.44.3.194","article-title":"Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate.","volume":"44","author":"Bax","year":"1985","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.60.10.913_bib34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/ard.46.3.177","article-title":"Long term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods.","volume":"46","author":"Situnayake","year":"1987","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.60.10.913_bib35","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/rheumatology\/36.3.382","article-title":"Sulphasalazine in the treatment of rheumatoid arthritis.","volume":"36","author":"Box","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.60.10.913_bib36","first-page":"1672","article-title":"Sulfasalazine in early rheumatoid arthritis.","volume":"19","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.60.10.913_bib37","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2125.1977.tb00797.x","article-title":"Anti-inflammatory analgesic drug responders and non-responders: a clinico-pharmacological study of flurbiprofen.","volume":"4","author":"Capell","year":"1977","journal-title":"Br J Clin Pharmacol"},{"key":"10.1136\/ard.60.10.913_bib38","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.1982.tb04958.x","article-title":"Variations in responses to non-steroidal anti-inflammatory drugs.","volume":"14","author":"Scott","year":"1982","journal-title":"Br J Clin Pharmacol"},{"key":"10.1136\/ard.60.10.913_bib39","first-page":"15","article-title":"Variability in response to NSAID.","volume":"17","author":"Day","year":"1985","journal-title":"Agents Actions Suppl"},{"key":"10.1136\/ard.60.10.913_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.1780330103","article-title":"Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis [see comments].","volume":"33","author":"Cush","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.10.913_bib41","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/art.1780401105","article-title":"Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis. Support for the concept of \u201cresponders\u201d and \u201cnonresponders\u201d.","volume":"40","author":"Walker","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.10.913_bib42","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/1529-0131(199909)42:9<1854::AID-ANR9>3.0.CO;2-F","article-title":"Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time.","volume":"42","author":"Drossaers-Bakker","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.10.913_bib43","first-page":"9","article-title":"The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome.","volume":"24","author":"Devlin","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.60.10.913_bib44","first-page":"425","article-title":"Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants.","volume":"21","author":"van Leeuwen","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.60.10.913_bib45","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1136\/ard.46.5.398","article-title":"Effect of sulphasalazine on the radiological progression of rheumatoid arthritis.","volume":"46","author":"Pullar","year":"1987","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.60.10.913_bib46","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(89)92442-2","article-title":"Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis.","volume":"i","author":"van der Heijde","year":"1989","journal-title":"Lancet"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724433566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724433566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.60.10.913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T05:25:13Z","timestamp":1737264313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724433566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,10]]}},"alternative-id":["S0003496724433566"],"URL":"https:\/\/doi.org\/10.1136\/ard.60.10.913","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2001,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.60.10.913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2001 Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}